仙灵骨葆胶囊肝毒性研究进展

doi:10.19803/j.1672-8629.20230107

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (5): 496-499.
DOI: 10.19803/j.1672-8629.20230107

• 中草药及抗肿瘤治疗相关肝损伤专栏（二） • 上一篇下一篇

仙灵骨葆胶囊肝毒性研究进展

朱春雾¹, 余雪君¹, 孙鑫^2,3, 刘成海^2,3,4,*

¹上海中医药大学附属普陀医院老年科,上海 200062;
²上海中医药大学附属曙光医院肝病研究所,上海 201203;
³上海市中医临床重点实验室,上海 201203;
⁴肝肾疾病病证教育部重点实验室,上海 201203

收稿日期:2023-02-27 出版日期:2023-05-15 发布日期:2023-05-16
通讯作者: ^*刘成海,男,博士,研究员,教授,中西医结合防治慢性肝病。E-mail: chenghailiu@hotmail.com
作者简介:朱春雾,女,硕士,主治医师,中西医结合治疗慢性肝病。
基金资助:
国家自然科学基金资助项目（81730109、82274305）; 上海市中医药事业发展三年行动计划[ZY(2018-2020)-CCCX-5001]; 上海市科学技术委员会科技计划项目（20Z21900100）; 上海市临床重点专科建设项目（shslczdzk01201）

Overview of hepatotoxicity of Xianling Gubao capsules

ZHU Chunwu¹, YU Xuejun¹, SUN Xin^2,3, LIU Chenghai^2,3,4,*

¹Department of Gerontology, Putuo Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200062, China;
²Institute of Liver Diseases, Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
³Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China;
⁴Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai 201203, China

Received:2023-02-27 Online:2023-05-15 Published:2023-05-16

摘要/Abstract

摘要： 目的分析仙灵骨葆胶囊的肝毒性,为其安全合理使用提供参考。方法通过查阅1994年1月1日至2022年8月31日国内外相关文献,从肝毒性表现、肝损伤的因素、毒性机制、减毒应对措施等方面对仙灵骨葆胶囊肝毒性研究概况进行整理和总结。结果仙灵骨葆胶囊的毒性成分主要是补骨脂和淫羊藿,与患者性别、年龄、药量等因素有关。结论临床使用中应加强仙灵骨葆胶囊肝毒性的监测,以减少肝损伤的发生。

关键词: 仙灵骨葆, 胶囊, 肝毒性, 药品不良反应, 肝损伤, 补骨脂, 淫羊藿

Abstract: Objective To analyze the hepatotoxicity of Xianling Gubao capsules and provide reference for its safe and reasonable use. Methods By referring to the relevant literature at home and abroad from January 1994 to August 2022, the research situation of liver toxicity of Xianling Gubao capsules from the aspects of liver toxicity, cause of liver injury, toxicity mechanism and attenuated countermeasures was summarized. Results The toxic components of Xianling Gubao capsules are mainly Psoraleae Fructus and Epimedii Folium, which are related to factors such as patient’s gender, age and dosage. Conclusion The monitoring of hepatotoxicity of Xianling Gubao capsules should be strengthened in clinical use to reduce the occurrence of liver injury.

Key words: Xianling Gubao, capsules, hepatotoxicity, adverse drug reaction, liver injury, Psoraleae Fructus, Epimedii Folium

中图分类号:

R977
R994.11

朱春雾, 余雪君, 孙鑫, 刘成海. 仙灵骨葆胶囊肝毒性研究进展[J]. 中国药物警戒, 2023, 20(5): 496-499.

ZHU Chunwu, YU Xuejun, SUN Xin, LIU Chenghai. Overview of hepatotoxicity of Xianling Gubao capsules[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 496-499.

参考文献

[1] JIN FY, LIANG GY, ZHANG Z, et al.Studies on the quality standard for Xianling Gubao capsule[J]. Chin Pharm J(中国药学杂志), 2002, 37(5): 54-57.
[2] National Medical Products Administration. National Medical Products Administration has drawn attention to the drug risks of Xianling Gubao oral preparation[EB/OL]. (2016-12-08)[2023-03-26]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20161208170501622.html.
[3] Drug induced Liver Disease Study Group, Chinese society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol(临床肝胆病杂志), 2015, 31(11): 1752-1769.
[4] PENG SY, XIE YM, WANG ZF, et al.Analysis of adverse reactions of Xianling Gubao preparation based on real world SRS data[J]. China J Chin Mater Med(中国中药杂志), 2020, 45(10): 2316-2321.
[5] WANG ZF, PENG SY, XIE YM, et al.Real world multi-dimensional design of clinical safety research on Xianling Gubao preparation[J]. World Chin Med(世界中医药), 2020, 15(1): 7-12.
[6] YANG YH, ZHOU YL.Liver dysfunction resulting from Xianlinggubao capsules in 2 cases[J]. Adv Drug React J(药物不良反应杂志), 2007, 9(3): 214-215.
[7] LI S, WANG XJ, ZHUANG W, et al.Analysis of 39 cases of adverse reactions/events in Xianling Gubao capsules[J]. China Pharmacist(中国药师), 2019, 22(6): 1068-1071.
[8] GUO ZJ, LI P, KANG QJ, et al.Safety analysis and consideration on hepatotoxicity of Psoralea corylifolia L.[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2022, 37(5): 2616-2621.
[9] QIN ZF, YAO ZH, DAI Y, et al.HPLC-MS/MS analysis of the absorbed components in serum after intragastric administration of Xianlinggubao to rats[J]. J Instrumental Anal(分析测试学报), 2013, 32(4): 420-426.
[10] LIN HW, JIANG HX, LU WS, et al.Study on hepatotoxicity of Xianling Gubao extract and its unilateral extracts[J]. Pharm Care Res(药学服务与研究), 2020, 20(2): 98-101.
[11] HUANG Y, LIU YL, MA RY, et al.Clinical case analysis and disassembled prescription study of liver injury related to Xianling Gubao[J]. Acta Pharm Sin(药学学报), 2021, 56(1): 266-273.
[12] GUO ZJ, ZHANG JX, KANG QJ, et al.Comparative study on hepatotoxicity of Psoraleae Fructus in rats and mice[J]. Chin J Exp Tradit Med Formul(中国实验方剂学杂志), 2020, 26(22): 16-25.
[13] YANG C, YAO C.Clinical analysis and treatment of 10 cases of liver injury caused by Xianlinggubao capsule[J]. Anti Infect Pharm(抗感染药学), 2021, 18(9): 1366-1369.
[14] WANG Y, ZHANG H, JIANG JM, et al.Hepatotoxicity induced by psoralen and isopsoralen from Fructus Psoraleae: Wistar rats are more vulnerable than ICR mice[J]. Food Chem Toxicol, 2019, 125: 133-140.
[15] ZHANG Y, BI YN, YUAN XM, et al.Study on hepatotoxic components of Psoraleae Fructus based on target organs[J]. Lishizhen Med Mater Med Res(时珍国医国药), 2017, 28(8): 1844-1847.
[16] HUANG JY, WANG Q, BI YN, et al.Effect of isopsoralen on hepatic function and bile acid transporters in SD rats with different administration periods[J]. Chin Pharmacol Bull(中国药理学通报), 2019, 35(2): 260-264.
[17] ZHONG YH, SHEN GL, YUAN M, et al.Evaluation of cytochrome P450 inhibition and induction by psoralen and isopsoralen in vitro[J]. Chin J Pharmacol Toxicol(中国药理学与毒理学杂志), 2012, 26(4): 522-528.
[18] ZHOU K, WANG AH, CHAI LJ, et al.Cytotoxicity of bakuchiol on HepG2 cells and effects of BSEP, NTCP, FXR, CYP7A1[J]. J Toxicol(毒理学杂志), 2015, 29(3): 193-196.
[19] HU XJ, ZHANG YB, ZHAO ZJ, et al.Metabolic detoxification of bakuchiol is mediated by oxidation of CYP 450s in liver microsomes[J]. Food Chem Toxicol, 2018, 111: 385-392.
[20] GUO ZJ.Study on drug factors, toxicity mechanism and material basis of Psoraleae Fructus hepatotoxicity[D]. Beijing: Beijing University of Traditional Chinese Medicine, 2021.
[21] GUO ZJ, LI P, WANG CG, et al.Five constituents contributed to the Psoraleae Fructus-induced hepatotoxicity via mitochondrial dysfunction and apoptosis[J]. Front Pharmacol, 2021, 12: 682823.
[22] ZHOU K, BI YN, SHI H.Psoralen induced bile acid accumulation and cytotoxicity by inhibiting MRP2 and MRP3 in HepG2 cells[J]. Chin Pharmacol Bull(中国药理学通报), 2015, 31(8): 1112-1116.
[23] ZHANG XJ, CAO HQ, XING ZH, et al.Effects of Psoralea corylifolia L. on hepatocyte morphology, liver function and mitochondrial membrane potential in mice[J]. Chin Tradit Patent Med(中成药), 2014, 36(1): 160-162.
[24] ZHANG Y, LI J, CHEN Y, et al.The role of hepatic antioxidant capacity and hepatobiliary transporter in liver injury induced by isopsoralen in zebrafish larvae[J]. Hum Exp Toxicol, 2018, 1(9): 1-9.
[25] WANG D, JIA DX, LI ZZ, et al.Discussion on safety evaluation and risk control measures of Epimedii Folium[J]. China J Chin Mater Med(中国中药杂志), 2019, 44(8): 1715.
[26] ZHANG L, ZHANG JX, FAN QY, et al.Hepatoxicity of epimedii folium in rat model based on uniform design and regression analysis[J]. Chin J Exp Tradit Med Formul(中国实验方剂学杂志), 2018, 24(6): 189-197.
[27] WANG ZL.Susceptible components and mechanism studies of Epimedii Folium-induced immunological idiosyncratic liver injury based on NLRP3 inflammasome[D]. Chengdu: Chengdu University of Traditional Chinese Medicine, 2021.
[28] GAO Y, WANG ZL, TANG JF, et al.New incompatible pair of TCM: Epimedii Folium combined with Psoraleae Fructus induces idiosyncratic hepatotoxicity under immunological stress conditions[J]. Front Med, 2020, 14: 68-80.
[29] CHENG JH, CAI HD.Adverse reactions to Zhuangguguanjie Wan and cause analysis[J]. Adv Drug React J(药物不良反应杂志), 2000, 1(1): 15-19.
[30] ZHU CW, WANG HN, ZHANG YL, et al.Liver injury caused by Xianlinggubao capsules[J]. Chin Hepatol(肝脏), 2018, 23(12): 1090-1093.
[31] YANG K.Sex difference characteristics and serum metabonomics study of liver injury in rats caused by psoralen and isopsoralen[D]. Nanchang: Jiangxi University of Traditional Chinese Medicine, 2021.
[32] ZHAO XW, XU CL.Hepatic injury and hepatitis B virus reactivation due to concomitant use of Xianlinggubao capsules and omeprazole[J]. Adv Drug React J(药物不良反应杂志), 2012, 14(1): 60-61.
[33] ZHENG MJ, ZHOU Y, LYU XQ.Xianlinggubao capsules combined with diclofenac sodium sustained-release capsules to cause liver failure: a case report[J]. Chinese Journel of Pharmacovigilance(中国药物警戒), 2014, 11(8): 507-508.
[34] GUO ZJ, ZHANG JX, TU C, et al.Thoughts on several issues of potential hepatotoxicity in Chinese medicines[J]. China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2020, 35(11): 5399-5402.
[35] CAO SS, GONG S, YAN M, et al.Preventive effects of Danshen on cisplatin-induced hepatotoxicity[J]. Chin Pharmacol Bull(中国药理学通报), 2017, 33(1): 144-145.
[36] LU S, GUO JL, BIAO YN, et al.Effect of Danshen and Zexie on lipid metabolism and PPARα gene expression[J]. J Hebei Tradit Chin Med Pharmacol(河北中医药学报), 2022, 37(2): 45-48.
[37] ZHANG YF, CHEN L.The study of liver toxicity protective effects of tanshinone ⅡA to isoniazid and rifampicin in mice[J]. Henan J Prev Med(河南预防医学杂志), 2011, 22(5): 399-400.
[38] CHEN ZY, HUANG JS, XU YJ, et al.TanshinoneⅡa alleviates acute liver and kidney injury in septic rats[J]. Chin J Immunol(中国免疫学杂志), 2020, 36(13): 1578-1582.
[39] WANG WL, JYU DH, LIU MJ, et al.Research progress on pharmacology of effective components of dipsacales[J]. Chin J Med Guide(中国医药导刊), 2015, 17(10): 1059-1060.
[40] SONG D, CHEN SS, LI PY, et al.Attenuating the potential hepato-toxicity of Psoraleae Fructus by pre-processing: the alcohol soaking and water rinsing method[J]. Acta Pharm Sin(药学学报), 2020, 55(2): 276-282.
[41] HONG L, WANG Z, TANG XH, et al.Processing of psoraleae fructus based on combination of Leigong method and salt processed method and its hepatotoxicity evaluation[J]. Chin Tradit Herb Drugs(中草药), 2021, 52(22): 6983-6989.

仙灵骨葆胶囊肝毒性研究进展

Overview of hepatotoxicity of Xianling Gubao capsules

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	王欣, 史磊磊, 张雨涵, 谢允东, 刘继平. 多药耐药相关蛋白转运体在药物性肝损伤中的作用研究进展[J]. 中国药物警戒, 2024, 21(2): 229-234.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[12]	曹姗, 庞博, 徐英莉, 张敬升, 陈梦苹, 张宇, 王雅欣, 包蕾, 耿子涵, 郭姗姗, 赵荣华, 崔晓兰. 疏风解毒胶囊预防给药对流感病毒感染小鼠模型TLR4介导肺组织炎性损伤的影响[J]. 中国药物警戒, 2024, 21(1): 45-50.
[13]	尚慧莹, 魏雪, 程宏愽, 马增春, 涂博丹, 肖成荣, 刘献, 高月. 基于高内涵技术的补骨脂肝毒性成分筛选研究[J]. 中国药物警戒, 2024, 21(1): 74-82.
[14]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[15]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.